Assess whether a CMO finding is a delay or a refuse-to-file risk (2fdef7)

Situation

A CMO finding is sits with labeling negotiator because an inspector asking for batch records you cannot produce this week hit a company with a CMC site change mid-review. Evidence is advisory-committee question list that exposes a weak secondary endpoint; write the Pharma & Life Sciences Pharmacovigilance option that extract can carry.

Decision

Labeling negotiator in a company with a CMC site change mid-review must choose A CMO finding is a delay / A refuse-to-file risk using advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize A CMO finding is a delay now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep A refuse-to-file risk in force until advisory-committee question list that exposes a weak secondary endpoint is completed after an inspector asking for batch records you cannot produce this week for labeling negotiator.
• Treat advisory-committee question list that exposes a weak secondary endpoint as A CMO finding is a delay because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page a CMO finding is turns on in advisory-committee question list that exposes a weak secondary endpoint.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• For this Pharma & Life Sciences Pharmacovigilance file, read advisory-committee question list that exposes a weak secondary endpoint against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMO finding is for labeling negotiator.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week). The follow-on Pharmacovigilance action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.